INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Praxis Precision Medicines, Inc. and its officers or directors [1] Financial Results - On August 4, 2025, Praxis reported its financial results for Q2 2025, including mid-stage study results for its anti-seizure medication vormatrigine [3] - The study revealed that 36 out of 61 patients experienced treatment-emergent adverse events, with nearly 25% of participants discontinuing the study [3] - Following the announcement, Praxis's stock price decreased by $3.00 per share, or 5.55%, closing at $51.09 per share on the same day [3]